Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00382096 · ClinicalTrials.gov registry record · Phase 3
Efficacy of Fixed Combination Therapy of Vildagliptin and Metformin Compared to the Individual Monotherapy Components in Drug Naive Patients With Type 2 Diabetes
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,179
- Enrollment target
NCT00382096 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,179 participants.
The verdict
NCT00382096, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,179 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of a fixed combination of vildagliptin and metformin in lowering blood glucose in patients with type 2 diabetes
Interventions
- DRUG Metformin
- DRUG Vildagliptin
- DRUG Vildagliptin + Metformin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,179 participants |
| Start Date | 2006-09 |
| Est. Completion | 2008-06-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00382096
The ClinicalTrials.gov registry entry for NCT00382096 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,179 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Metformin is the first listed.
NCT00382096 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00382096 about?
NCT00382096 is a clinical study titled "Efficacy of Fixed Combination Therapy of Vildagliptin and Metformin Compared to the Individual Monotherapy Components in Drug Naive Patients With Type 2 Diabetes". The purpose of this study is to evaluate the efficacy and safety of a fixed combination of vildagliptin and metformin in lowering blood glucose in patients with type 2 diabetes
What is the current status of trial NCT00382096?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,179 participants. The study started on 2006-09. Estimated completion is 2008-06-03.
What interventions are being tested in trial NCT00382096?
The interventions under investigation include: Metformin (DRUG), Vildagliptin (DRUG), Vildagliptin + Metformin (DRUG).
Who is sponsoring clinical trial NCT00382096?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.